REPROCESSABLE COMPOSITIONS

Abstract

The present disclosure provides compositions comprising: a) a copolymer prepared by a method comprising polymerizing in the presence of a metathesis catalyst: i) a first monomer, wherein each instance of the first monomer is independently of the formula:

##STR00001## or salt thereof; ii) a second monomer, wherein each instance of the second monomer is independently of the formula:

##STR00002## or a salt thereof; iii) optionally a third monomer, wherein the third monomer is different from the first monomer and the second monomer; and iv) optionally a reprocessing catalyst; and b) optionally the reprocessing catalyst; wherein the reprocessing catalyst is a Brønsted acid, Lewis acid, Brønsted base, Lewis base, or a salt thereof; provided that the composition comprises at least one of the reprocessing catalyst of iv) and the reprocessing catalyst of b). The compositions may be reprocessed (e.g., remolded) under elevated temperature and/or elevated pressure.

Claims

1. A composition comprising: a) a copolymer prepared by a method comprising polymerizing in the presence of a metathesis catalyst: i) a first monomer, wherein each instance of the first monomer is independently of the formula: ##STR00061## or salt thereof, wherein: each instance of Z is independently a single bond, C(R.sup.P).sub.2, or O; each instance of R.sup.P is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; each instance of custom-character is independently a single or double bond; each instance of R.sup.H is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR.sup.a, —OCN, —OC(═O)R.sup.a, —OC(═S)R.sup.a, —OC(═O)OR.sup.a, —OC(═O)N(R.sup.a).sub.2, —OS(═O)R.sup.a, —OS(═O)OR.sup.a, —OS(═O)N(R.sup.a).sub.2, —OS(═O).sub.2R.sup.a, —OS(═O).sub.2OR.sup.a, —OS(═O).sub.2N(R.sup.a).sub.2, —OSi(R.sup.a).sub.3, —OSi(R.sup.a).sub.2(OR.sup.a), —OSi(R.sup.a)(OR.sup.a).sub.2, —OSi(OR.sup.a).sub.3, oxo, —N(R.sup.a).sub.2, —N═C(R.sup.a).sub.2, ═NR.sup.a, —NC, —NCO, —N.sub.3, —NO.sub.2, —NR.sup.aC(═O)R.sup.a, —NR.sup.aC(═O)OR.sup.a, —NR.sup.aC(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O)R.sup.a, —NR.sup.aS(═O)OR.sup.a, —NR.sup.aS (═O)N(R.sup.a).sub.2, —NR.sup.aS(═O).sub.2R.sup.a, —NR.sup.aS(═O).sub.2OR.sup.a, —NR.sup.aS(═O).sub.2N(R.sup.a).sub.2, —SR.sup.a, —SCN, —S(═O)R.sup.a, —S(═O)OR.sup.a, —S(═O)N(R.sup.a).sub.2, —S(═O).sub.2R.sup.a, —S(═O).sub.2OR.sup.a, —S(═O).sub.2N(R.sup.a).sub.2, —SeR.sup.a, halogen, —CN, —C(═NR.sup.a)R.sup.a, —C(═NR.sup.a)OR.sup.a, —C(═NR.sup.a)N(R.sup.a).sub.2, —C(═O)R.sup.a, —C(═O)OR.sup.a, —C(═O)SR.sup.a, —C(═S)OR.sup.a, or —C(═O)N(R.sup.a).sub.2; or the two instances of R.sup.H of one or more instances of ##STR00062## are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring; and each instance of R.sup.a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R.sup.a are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl; ii) a second monomer, wherein each instance of the second monomer is independently of the formula: ##STR00063## or a salt thereof, wherein: each instance of Y is independently O or C(R.sup.Q).sub.2; each instance of R.sup.Q is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; each instance of R.sup.K is independently hydrogen, halogen, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or —OR.sup.N; each instance of R.sup.N is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; each instance of j is independently 1, 2, or 3; in Formulae (B) and (B1), each instance of k is independently 0, 1, 2, or 3; and in Formula (B2): W is carbon or silicon; each instance of R.sup.Y is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; each instance of R.sup.Z is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; R.sup.K1 is hydrogen, halogen, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted, C.sub.2-10 alkenyl, substituted or unsubstituted, C.sub.2-10 alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L.sup.K1-(substituted or unsubstituted carbocyclyl), -L.sup.K1-(substituted or unsubstituted heterocyclyl), -L.sup.K1-(substituted or unsubstituted aryl), -L.sup.K1-(substituted or unsubstituted heteroaryl), or —OR.sup.N1; L.sup.K1 is —O—, substituted or unsubstituted, C.sub.1-10 alkylene, substituted or unsubstituted, C.sub.2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; R.sup.N1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; R.sup.K2 is halogen, substituted or unsubstituted, C.sub.2-10 alkenyl, substituted or unsubstituted, C.sub.2-10 alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, -L.sup.K2-(substituted or unsubstituted carbocyclyl), -L.sup.K2-(substituted or unsubstituted heterocyclyl), -L.sup.K2-(substituted or unsubstituted aryl), or —OR.sup.N2; L.sup.K2 is —O—, substituted or unsubstituted, C.sub.1-10 alkylene, substituted or unsubstituted, C.sub.2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; R.sup.N2 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; or R.sup.K1 and R.sup.K2 are joined with the intervening atom to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; and each instance of k is independently 1, 2, or 3; iii) optionally a third monomer, wherein the third monomer is different from the first monomer and the second monomer; and iv) optionally a reprocessing catalyst; and b) optionally the reprocessing catalyst; wherein the reprocessing catalyst is a Brønsted acid, Lewis acid, Brønsted base, Lewis base, urea, thiourea, carbamate, thiocarbamate, or a salt thereof; provided that the composition comprises at least one of the reprocessing catalyst of iv) and the reprocessing catalyst of b).

2-4. (canceled)

5. A kit comprising: a) a copolymer prepared by a method comprising polymerizing in the presence of a metathesis catalyst: i) a first monomer, wherein each instance of the first monomer is independently of the formula: ##STR00064## or salt thereof, wherein: each instance of Z is independently a single bond, C(R.sup.P).sub.2, or O; each instance of R.sup.P is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; each instance of custom-character is independently a single or double bond; each instance of R.sup.H is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR.sup.a, —OCN, —OC(═O)R.sup.a, —OC(═S)R.sup.a, —OC(═O)OR.sup.a, —OC(═O)N(R.sup.a).sub.2, —OS(═O)R.sup.a, —OS(═O)OR.sup.a, —OS(═O)N(R.sup.a).sub.2, —OS(═O).sub.2R.sup.a, —OS(═O).sub.2OR.sup.a, —OS(═O).sub.2N(R.sup.a).sub.2, —OSi(R.sup.a).sub.3, —OSi(R.sup.a).sub.2(OR.sup.a), —OSi(R.sup.a)(OR.sup.a).sub.2, —OSi(OR.sup.a).sub.3, oxo, —N(R.sup.a).sub.2, —N═C(R.sup.a).sub.2, ═NR.sup.a, —NC, —NCO, —N.sub.3, —NO.sub.2, —NR.sup.aC(═O)R.sup.a, —NR.sup.aC(═O)OR.sup.a, —NR.sup.aC(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O)R.sup.a, —NR.sup.aS(═O)OR.sup.a, —NR.sup.aS(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O).sub.2R.sup.a, —NR.sup.aS(═O).sub.2OR.sup.a, —NR.sup.aS(═O).sub.2N(R.sup.a).sub.2, —SR.sup.a, —SCN, —S(═O)R.sup.a, —S(═O)OR.sup.a, —S(═O)N(R.sup.a).sub.2, —S(═O).sub.2R.sup.a, —S(═O).sub.2OR.sup.a, —S(═O).sub.2N(R.sup.a).sub.2, —SeR.sup.a, halogen, —CN, —C(═NR.sup.a)R.sup.a, —C(═NR.sup.a)OR.sup.a, —C(═NR.sup.a)N(R.sup.a).sub.2, —C(═O)R.sup.a, —C(═O)OR.sup.a, —C(═O)SR.sup.a, —C(═S)OR.sup.a, or —C(═O)N(R.sup.a).sub.2; or the two instances of R.sup.H of one or more instances of ##STR00065## are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring; and each instance of Ra is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of Ra are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl; ii) a second monomer, wherein each instance of the second monomer is independently of the formula: ##STR00066## or a salt thereof, wherein: each instance of Y is independently O or C(R.sup.Q).sub.2; each instance of R.sup.Q is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; each instance of R.sup.K is independently hydrogen, halogen, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or —OR.sup.N; each instance of R.sup.N is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; each instance of j is independently 1, 2, or 3; in Formulae (B) and (B1), each instance of k is independently 0, 1, 2, or 3; and in Formula (B2): W is carbon or silicon; each instance of R.sup.Y is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; each instance of R.sup.Z is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; R.sup.K1 is hydrogen, halogen, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted, C.sub.2-10 alkenyl, substituted or unsubstituted, C.sub.2-10 alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L.sup.K1-(substituted or unsubstituted carbocyclyl), -L.sup.K1-(substituted or unsubstituted heterocyclyl), -L.sup.K1-(substituted or unsubstituted aryl), -L.sup.K1-(substituted or unsubstituted heteroaryl), or —OR.sup.N1; L.sup.K1 is —O—, substituted or unsubstituted, C.sub.1-10 alkylene, substituted or unsubstituted, C.sub.2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; R.sup.N1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; R.sup.K2 is halogen, substituted or unsubstituted, C.sub.2-10 alkenyl, substituted or unsubstituted, C.sub.2-10 alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, -L.sup.K2-(substituted or unsubstituted carbocyclyl), -L.sup.K2-(substituted or unsubstituted heterocyclyl), -L.sup.K2-(substituted or unsubstituted aryl), or —OR.sup.N2; L.sup.K2 is —O—, substituted or unsubstituted, C.sub.1-10 alkylene, substituted or unsubstituted, C.sub.2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; R.sup.N2 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; or R.sup.K1 and R.sup.K2 are joined with the intervening atom to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; and each instance of k is independently 1, 2, or 3; iii) optionally a third monomer, wherein the third monomer is different from the first monomer and the second monomer; and iv) optionally a reprocessing catalyst; and b) the reprocessing catalyst; wherein the reprocessing catalyst is a Brønsted acid, Lewis acid, Brønsted base, Lewis base, urea, thiourea, carbamate, thiocarbamate, or a salt thereof.

6. A method of preparing the composition of claim 1 comprising mixing the copolymer with the reprocessing catalyst of b).

7-12. (canceled)

13. A method of preparing the composition of claim 1 comprising polymerizing: the first monomer; the second monomer; and optionally the third monomer; in the presence of the metathesis catalyst and the reprocessing catalyst of iv).

14-15. (canceled)

16. A method of reprocessing the composition of claim 1 comprising: heating the composition to an elevated temperature, wherein the elevated temperature is between 40 and 400° C., inclusive; and/or pressing the composition to an elevated pressure, wherein the elevated pressure is between 0.1 and 1,000 ton/ft.sup.2, inclusive; wherein during a time period between 1 hour and 2 weeks, inclusive, the elevated temperature and/or the elevated pressure are substantially maintained.

17-27. (canceled)

28. The composition of claim 1, wherein at least one instance of the first monomer is of the formula: ##STR00067##

29. (canceled)

30. The composition of claim 1, wherein at least one instance of the second monomer is of the formula: ##STR00068## or a salt thereof.

31. The composition of claim 1, wherein at least one instance of the second monomer is of the formula: ##STR00069## or a salt thereof.

32. The composition of claim 1, wherein at least one instance of the second monomer is of the formula: ##STR00070##

33. The composition of claim 1, wherein at least one instance of the second monomer is of the formula: ##STR00071## or a salt thereof.

34. The composition of claim 1, wherein at least one instance of the second monomer is of the formula: ##STR00072##

35. The composition of claim 1, wherein at least one instance of the second monomer is of the formula: ##STR00073## or a salt thereof.

36. The composition of claim 1, wherein at least one instance of the second monomer is of the formula: ##STR00074## or a salt thereof.

37-84. (canceled)

85. The composition of claim 1, wherein each instance of the second monomer comprises only one non-aromatic unsaturated bond.

86. The composition of claim 1, wherein at least one instance of the second monomer is of the formula: ##STR00075##

87. The composition of claim 1, wherein at least one instance of the second monomer is of the formula: ##STR00076##

88. The composition of claim 1, wherein at least one instance of the second monomer is of the formula: ##STR00077##

89. The composition of claim 1, wherein the molar ratio of the first monomer to the second monomer is between 1:1 and 100:1, inclusive.

90-92. (canceled)

93. The composition of claim 1, wherein the ratio of the combined molar amounts of the first monomer, second monomer, and third monomer if present to the molar amount of the metathesis catalyst is between 500:1 and 500,000:1, inclusive.

94-96. (canceled)

97. The composition of claim 1, wherein the average molecular weight of the copolymer as determined by gel permeation chromatography is between 10 kDa and 100,000 kDa, inclusive.

98. (canceled)

99. The composition of claim 1, wherein the reprocessing catalyst is a Brønsted acid, or a salt thereof.

100-101. (canceled)

102. The composition of claim 1, wherein the reprocessing catalyst is a carboxylic acid.

103-111. (canceled)

112. The composition of claim 1, wherein the molar ratio of the second monomer to the reprocessing catalyst is between 30:1 and 1:10, inclusive.

113. (canceled)

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0078] The figures are exemplary and do not limit the scope of the present disclosure.

[0079] FIG. 1 shows iPrSi-

##STR00006##

and reprocessing-catalyst-dependent remolding of a copolymer prepared by polymerizing in the presence of a Grubbs' catalyst dicyclopentadiene (DCPD, a first monomer) and iPrSi (a second monomer). The copolymer is referred to as DCPD-co-iPrSi. DCPD-co-iPrSi pressed at 1 ton/ft.sup.2 did not appear to heal. DCPD-co-iPrSi pressed at 170° C. showed some browning.

[0080] FIGS. 2A and 2B show iPrSi- and reprocessing-catalyst-dependent remolding of DCPD-co-iPrSi of dynamic strands and dynamic crosslinkers under the following conditions: 130° C., 24 hr, 6 ton/ft.sup.2 pressure. Octanoic acid (OA) as the reprocessing catalyst (“cat.”). DCPD-co-iPrSi remolded in an iPrSi- and reprocessing-catalyst-dependent manner (FIG. 2A). A copolymer DCPD-co-iPrSi-co-SiXL, which was prepared by polymerizing in the presence of a Grubbs' catalyst DCPD, iPrSi, and 40%

##STR00007##

(SiXL) did not remold, even in the presence of 1 or 5 phr octanoic acid (FIG. 2B). This suggests dynamic bond location may be an important design parameter in the compositions described herein. This has been demonstrated as successful with both 7-member and 8-member second monomers. The term “phr” refers to part per hundred by mass.

[0081] FIG. 3 shows presence of octanoic acid and iPrSi enabled extreme swelling. Left: a composition comprising DCPD-co-iPrSi (where iPrSi was 10%) and 5 phr octanoic acid swelled in THF for 1 month. The composition swelled to complete size of container and incorporated all THF, indicating that exchange had occurred to allow relaxation and expansion to swell. Right: a composition comprising poly-DCPD (where iPrSi was 0%) and 5 phr octanoic acid swelled in THF for 1 month. The composition roughly doubled in size, and octanoic acid did not appear to improve the ability of native poly-DCPD to swell in THF.

[0082] FIGS. 4A to 4C show the chemical composition of octanoic acid and its possible role. FIG. 4A shows a possible reaction mechanism. At elevated temperature, reaction occurs to minute extent in absence of octanoic acid (“no cat.”), as shown by a GC-MS spectrum of the reaction mixture (FIG. 4B). Reaction occurs significantly with 10% octanoic acid at hot-press temperatures, as shown by a GC-MS spectrum of the reaction mixture (FIG. 4C).

[0083] FIGS. 5A to 5G show a possible role of the reprocessing catalyst. FIG. 5A shows a possible reaction mechanism. Compositions comprising DCPD-co-iPrSi and a reprocessing catalyst were left at 180° C. for 18 hours. Some exchange occurs in absence of the reprocessing catalyst (FIG. 5B). Significant exchange occurred with octanoic acid (FIG. 5C). Ammonium chloride seemed to show little exchange (FIG. 5F). 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) showed some exchange (FIG. 5D). Zn(acac).sub.2 seemed to completely halt exchange (FIG. 5G). Camphor sulfonic acid (CSA) most rapidly catalyzed exchange (FIG. 5E).

[0084] FIGS. 6A to 6F show time- and reprocessing-catalyst-dependent exchange. FIG. 6A shows a possible reaction mechanism. FIG. 6B, top panel: 180° C.; no catalyst. FIG. 6B, bottom panel: 180° C.; octanoic acid (10%). FIG. 6C, top panel: 160° C.; no catalyst. FIG. 6C, bottom panel: 160° C.; octanoic acid (10%). FIG. 6D, top panel: 140° C.; no catalyst. FIG. 6D, bottom panel: 140° C.; octanoic acid (10%). FIG. 6E, top panel: 120° C.; no catalyst. FIG. 6E, bottom panel: 120° C.; octanoic acid (10%). FIG. 6F, top panel: 100° C.; no catalyst. FIG. 6F, bottom panel: 100° C.; octanoic acid (10%).

[0085] FIG. 7 is a schematic showing a synthesis of a DCPD-co-iPrSi.

[0086] FIG. 8 is a schematic showing the incorporation of dynamic linkages may enable bond exchange in DCPD-co-iPrSi, which may be useful for self-healing of DCPD-co-iPrSi. “Catalyst” refers to reprocessing-catalyst.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE DISCLOSURE

[0087] The details of certain embodiments of the invention are set forth in the present section. Other features, objects, and advantages of the invention will be apparent from the Definitions, Figures, Examples, and Claims. The aspects described herein are not limited to specific embodiments, methods, apparati, or configurations, and as such can, of course, vary. The terminology used herein is for the purpose of describing particular aspects only and, unless specifically defined herein, is not intended to be limiting.

[0088] In one aspect, the present disclosure provides compositions comprising:

[0089] a) a copolymer prepared by a method comprising polymerizing in the presence of a metathesis catalyst: [0090] i) a first monomer, wherein each instance of the first monomer is independently of the formula:

##STR00008##

[0091] or salt thereof, wherein: [0092] each instance of Z is independently a single bond, C(R.sup.P).sub.2, or O; [0093] each instance of R.sup.P is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; [0094] each instance of custom-character is independently a single or double bond; [0095] each instance of R.sup.H is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR.sup.a, —OCN, —OC(═O)R.sup.a, —OC(═S)R.sup.a, —OC(═O)OR.sup.a, —OC(═O)N(R.sup.a).sub.2, —OS(═O)R.sup.a, —OS(═O)OR.sup.a, —OS(═O)N(R.sup.a).sub.2, —OS(═O).sub.2R.sup.a, —OS(═O).sub.2OR.sup.a, —OS(═O).sub.2N(R.sup.a).sub.2, —OSi(R.sup.a).sub.2, —OSi(R.sup.a).sub.2(OR.sup.a), —OSi(R.sup.a)(OR.sup.a).sub.2, —OSi(OR.sup.a).sub.3, oxo, —N(R.sup.a).sub.2, —N═C(R.sup.a).sub.2, ═NR.sup.a, —NC, —NCO, —N.sub.3, —NO.sub.2, —NR.sup.aC(═O)R.sup.a, —NR.sup.aC(═O)OR.sup.a, —NR.sup.aC(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O)R.sup.a, —NR.sup.aS(═O)OR.sup.a, —NR.sup.aS(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O).sub.2R.sup.a, —NR.sup.aS(═O).sub.2OR.sup.a, —NR.sup.aS(═O).sub.2N(R.sup.a).sub.2, —SR.sup.a, —SCN, —S(═O)R.sup.a, —S(═O)OR.sup.a, —S(═O)N(R.sup.a).sub.2, —S(═O).sub.2R.sup.a, —S(═O).sub.2OR.sup.a, —S(═O).sub.2N(R.sup.a).sub.2, —SeR.sup.a, halogen, —CN, —C(═NR.sup.a)R.sup.a, —C(═NR.sup.a)OR.sup.a, —C(═NR.sup.a)N(R.sup.a).sub.2, —C(═O)R.sup.a, —C(═O)OR.sup.a, —C(═O)SR.sup.a, —C(═S)OR.sup.a, or —C(═O)N(R.sup.a).sub.2; [0096] or the two instances of R.sup.H of one or more instances of

##STR00009##

are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring; and [0097] each instance of R.sup.a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R.sup.a are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl; [0098] ii) a second monomer, wherein each instance of the second monomer is independently of the formula:

##STR00010##

[0099] or a salt thereof, wherein: [0100] each instance of Y is independently O or C(R.sup.Q).sub.2; [0101] each instance of R.sup.Q is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; [0102] each instance of R.sup.K is independently hydrogen, halogen, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or —OR.sup.N; [0103] each instance of R.sup.N is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; [0104] each instance of j is independently 1, 2, or 3; [0105] in Formulae (B) and (B1), each instance of k is independently 0, 1, 2, or 3; and [0106] in Formula (B2): [0107] W is carbon or silicon; [0108] each instance of R.sup.Y is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; [0109] each instance of R.sup.Z is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; [0110] R.sup.K1 is hydrogen, halogen, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted, C.sub.2-10 alkenyl, substituted or unsubstituted, C.sub.2-10alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L.sup.K1-(substituted or unsubstituted carbocyclyl), -L.sup.K1-(substituted or unsubstituted heterocyclyl), -L.sup.K1-(substituted or unsubstituted aryl), -L.sup.K1-(substituted or unsubstituted heteroaryl), or OR.sup.N1; [0111] L.sup.K1 is —O—, substituted or unsubstituted, C.sub.1-10 alkylene, substituted or unsubstituted, C.sub.2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; [0112] R.sup.N1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; [0113] R.sup.K2 is halogen, substituted or unsubstituted, C.sub.2-10 alkenyl, substituted or unsubstituted, C.sub.2-10 alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, -L.sup.K2-(substituted or unsubstituted carbocyclyl), -L.sup.K2-(substituted or unsubstituted heterocyclyl), -L.sup.K2-(substituted or unsubstituted aryl), or —OR.sup.N2; [0114] L.sup.K2 is —O—, substituted or unsubstituted, C.sub.1-10 alkylene, substituted or unsubstituted, C.sub.2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; [0115] R.sup.N2 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; [0116] or R.sup.K1 and R.sup.K2 are joined with the intervening atom to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; and [0117] each instance of k is independently 1, 2, or 3; [0118] iii) optionally a third monomer, wherein the third monomer is different from the first monomer and the second monomer; and [0119] iv) optionally a reprocessing catalyst; and

[0120] b) optionally the reprocessing catalyst;

[0121] wherein the reprocessing catalyst is a Brønsted acid, Lewis acid, Brønsted base, Lewis base, urea, thiourea, carbamate, thiocarbamate, or a salt thereof;

[0122] provided that the composition comprises at least one of the reprocessing catalyst of iv) and the reprocessing catalyst of b).

[0123] In certain embodiments, the composition comprises at least the reprocessing catalyst of b).

[0124] In certain embodiments, the composition comprises the reprocessing catalyst of b) and substantially free of the reprocessing catalyst of iv).

[0125] In certain embodiments, the copolymer and the reprocessing catalyst of b) are in the form of a mixture of each other. In certain embodiments, the mixture is substantially free of solvents.

[0126] In certain embodiments, the composition comprises at least the reprocessing catalyst of iv).

[0127] In certain embodiments, the composition comprises the reprocessing catalyst of iv) and substantially free of the reprocessing catalyst of b).

[0128] In another aspect, the present disclosure provides kits comprising:

[0129] a) a copolymer prepared by a method comprising polymerizing in the presence of a metathesis catalyst: [0130] i) a first monomer, wherein each instance of the first monomer is independently of the formula:

##STR00011##

[0131] or salt thereof, wherein: [0132] each instance of Z is independently a single bond, C(R.sup.P).sub.2, or O; [0133] each instance of R.sup.P is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; [0134] each instance of custom-character is independently a single or double bond; [0135] each instance of R.sup.H is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR.sup.a, —OCN, —OC(═O)R.sup.a, —OC(═S)R.sup.a, —OC(═O)OR.sup.a, —OC(═O)N(R.sup.a).sub.2, —OS(═O)R.sup.a, —OS(═O)OR.sup.a, —OS(═O)N(R.sup.a).sub.2, —OS(═O).sub.2R.sup.a, —OS(═O).sub.2OR.sup.a, —OS(═O).sub.2N(R.sup.a).sub.2, —OSi(R.sup.a).sub.3, —OSi(R.sup.a).sub.2(OR.sup.a), —OSi(R.sup.a)(OR.sup.a).sub.2, —OSi(OR.sup.a).sub.3, oxo, —N(R.sup.a).sub.2, —N═C(R.sup.a).sub.2, ═NR.sup.a, —NC, —NCO, —N.sub.3, —NO.sub.2, —NR.sup.aC(═O)R.sup.a, —NR.sup.aC(═O)OR.sup.a, —NR.sup.aC(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O)R.sup.a, —NR.sup.aS(═O)OR.sup.a, —NR.sup.aS(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O).sub.2R.sup.a, —NR.sup.aS(═O).sub.2OR.sub.a, —NR.sup.aS(═O).sub.2N(R.sup.a).sub.2, —SR.sup.a, —SCN, —S(═O)R.sup.a, —S(═O)OR.sup.a, —S(═O)N(R.sup.a).sub.2, —S(═O).sub.2R.sup.a, —S(═O).sub.2OR.sub.a, —S(═O).sub.2N(R.sup.a).sub.2, —SeR.sup.a, halogen, —CN, —C(═NR.sup.a)R.sup.a, —C(═NR.sup.a)OR.sup.a, —C(═NR.sup.a)N(R.sup.a).sub.2, —C(═O)R.sup.a, —C(═O)OR.sup.a, —C(═O)SR.sup.a, —C(═S)OR.sup.a, or —C(═O)N(R.sup.a).sub.2; [0136] or the two instances of R.sup.H of one or more instances of

##STR00012##

are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring; and [0137] each instance of R.sup.a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of Ra are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl; [0138] ii) a second monomer, wherein each instance of the second monomer is independently of the formula:

##STR00013##

[0139] or a salt thereof, wherein: [0140] each instance of Y is independently O or C(R.sup.Q).sub.2; [0141] each instance of R.sup.Q is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; [0142] each instance of R.sup.K is independently hydrogen, halogen, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or —OR.sup.N; [0143] each instance of R.sup.N is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; [0144] each instance of j is independently 1, 2, or 3; [0145] in Formulae (B) and (B1), each instance of k is independently 0, 1, 2, or 3; and [0146] in Formula (B2): [0147] W is carbon or silicon; [0148] each instance of R.sup.Y is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; [0149] each instance of R.sup.Z is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl; [0150] R.sup.K1 is hydrogen, halogen, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted, C.sub.2-10 alkenyl, substituted or unsubstituted, C.sub.2-10 alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L.sup.K1-(substituted or unsubstituted carbocyclyl), -L.sup.K1-(substituted or unsubstituted heterocyclyl), -L.sup.K1-(substituted or unsubstituted aryl), -L.sup.K1-(substituted or unsubstituted heteroaryl), or —OR.sup.N1; [0151] L.sup.K1 is —O—, substituted or unsubstituted, C.sub.1-10 alkylene, substituted or unsubstituted, C.sub.2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; [0152] R.sup.N1 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; [0153] R.sup.K2 is halogen, substituted or unsubstituted, C.sub.2-10 alkenyl, substituted or unsubstituted, C.sub.2-10 alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, -L.sup.K2--(substituted or unsubstituted carbocyclyl), -L.sup.K2-(substituted or unsubstituted heterocyclyl), -L.sup.K2-(substituted or unsubstituted aryl), or —OR.sup.N2; [0154] L.sup.K2 is —O—, substituted or unsubstituted, C.sub.1-10 alkylene, substituted or unsubstituted, C.sub.2-10 heteroalkylene, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, or a combination thereof; [0155] R.sup.N2 is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or an oxygen protecting group; [0156] or R.sup.K1 and R.sup.K2 are joined with the intervening atom to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; and [0157] each instance of k is independently 1, 2, or 3; [0158] iii) optionally a third monomer, wherein the third monomer is different from the first monomer and the second monomer; and [0159] iv) optionally a reprocessing catalyst; and [0160] b) the reprocessing catalyst; [0161] wherein the reprocessing catalyst is a Brønsted acid, Lewis acid, Brønsted base, Lewis base, urea, thiourea, carbamate, thiocarbamate, or a salt thereof.

[0162] In another aspect, the present disclosure provides methods of preparing the composition described herein comprising mixing the copolymer with the reprocessing catalyst of b).

[0163] In certain embodiments, the step of mixing comprises the presence of a solvent and subsequent substantial removal of the solvent.

[0164] In certain embodiments, the solvent is an organic solvent.

[0165] In certain embodiments, the solvent is an aprotic organic solvent. In certain embodiments, the solvent is an aprotic ether solvent. In certain embodiments, the solvent is THF. In certain embodiments, the solvent is 2-methyltetrahydrofuran, methyl tertiary-butyl ether, or 1,4-dioxane. In certain embodiments, the boiling point of the solvent at a pressure of 1 atm is between 50 and 60, between 60 and 70, between 70 and 80, between 80 and 100, or between 100 and 120° C., inclusive.

[0166] In certain embodiments, the presence of a solvent comprises the presence of the solvent at a temperature between 20 and 30° C., inclusive. In certain embodiments, the presence of a solvent comprises the presence of the solvent at a temperature between 0 and 20, between 30 and 40, or between 40 and 60° C., inclusive. In certain embodiments, the presence of a solvent comprises the presence of the solvent at a temperature between 5 and 10, between 10 and 20, between 20 and 40, or between 40 and 60° C., inclusive, below the boiling point of the solvent at a pressure of 1 atm.

[0167] In certain embodiments, the solvent is present in the mixture resulted from the step of mixing for a time period between 1 hour and 2 weeks, inclusive.

[0168] In certain embodiments, the subsequent substantial removal of the solvent comprises subsequent substantial removal of the solvent at a pressure between 0.0001 and 0.1 atm, inclusive. In certain embodiments, the subsequent substantial removal of the solvent comprises subsequent substantial removal of the solvent at a pressure between 0.0001 and 0.001, between 0.001 and 0.01, between 0.01 and 0.1, or between 0.1 and 1 atm, inclusive.

[0169] In certain embodiments, the subsequent substantial removal of the solvent further comprises subsequent substantial removal of the solvent at a temperature between 0 and 20° C., inclusive, lower than the boiling point of the solvent. In certain embodiments, the subsequent substantial removal of the solvent further comprises subsequent substantial removal of the solvent at a temperature between 0 and 10, between 10 and 20, or between 20 and 40° C., inclusive, lower than the boiling point of the solvent.

[0170] Unless otherwise provided, the boiling point of the solvent is the boiling point of the solvent at a pressure of 1 atm.

[0171] In certain embodiments, the method of preparing the composition described herein further comprises, prior to the step of mixing, reducing the size of the composition.

[0172] In certain embodiments, the average size (e.g., average length or average diameter) of the composition after the step of reducing the size of the composition and prior to the step of mixing is between 1 μm and 1 mm, inclusive.

[0173] In another aspect, the present disclosure provides methods of preparing the composition of claim 1 comprising polymerizing:

[0174] the first monomer;

[0175] the second monomer; and

[0176] optionally the third monomer;

[0177] in the presence of the metathesis catalyst and the reprocessing catalyst of iv).

[0178] In certain embodiments, the step of polymerizing is substantially free of a solvent.

[0179] In certain embodiments, the step of polymerizing is substantially free of a chain transfer agent.

[0180] In certain embodiments, “substantially free” is between 90% and 95%, between 95% and 97%, between 97% and 99%, between 99% and 99.5%, or between 99.5% and 99.9%, free.

[0181] In another aspect, the present disclosure provides methods of reprocessing the composition of claim 1 comprising:

[0182] heating the composition to an elevated temperature, wherein the elevated temperature is between 40 and 400° C., inclusive; and/or

[0183] pressing the composition to an elevated pressure, wherein the elevated pressure is between 0.1 and 1,000 ton/ft.sup.2, inclusive;

[0184] wherein during a time period between 1 hour and 2 weeks, inclusive, the elevated temperature and/or the elevated pressure are substantially maintained.

[0185] In certain embodiments, the method comprises:

[0186] heating the composition to the elevated temperature; and

[0187] pressing the composition to the elevated pressure;

[0188] wherein during the time period, the elevated temperature and the elevated pressure are substantially maintained.

[0189] In certain embodiments, the elevated temperature is between 120 and 180° C., inclusive. In certain embodiments, the elevated temperature is between 150 and 170° C., inclusive. In certain embodiments, the elevated temperature is between 80 and 100 or between 100 and 120, inclusive. In certain embodiments, the elevated temperature is between 120 and 140, between 140 and 160, between 160 and 180, or between 180 and 200° C., inclusive.

[0190] In certain embodiments, the elevated pressure is between the ambient pressure and 1,000 ton/ft.sup.2, exclusive. In certain embodiments, the elevated pressure is between 1 and 30 ton/ft.sup.2, inclusive. In certain embodiments, the elevated pressure is between 3 and 12 ton/ft.sup.2, inclusive. In certain embodiments, the elevated pressure is between 1 and 10, between 10 and 20, between 20 and 30, between 30 and 40, between 40 and 60, between 60 and 100, between 100 and 300, or between 300 and 1000, ton/ft.sup.2, inclusive.

[0191] In certain embodiments, the time period is between 8 hours and 3 days, inclusive. In certain embodiments, the time period is between 8 hours and 3 days, inclusive. In certain embodiments, the time period is between 1 and 8 hours, between 8 and 24 hours, between 1 and 3 days, between 3 and 7 days, or between 7 and 14 days.

[0192] In certain embodiments, “at least one instance” is each instance.

[0193] In certain embodiments, at least one instance of Z is C(R.sup.P).sub.2. In certain embodiments, each instance of Z is C(R.sup.P).sub.2. In certain embodiments, at least one instance of Z is CH.sub.2. In certain embodiments, each instance of Z is CH.sub.2.

[0194] In certain embodiments, each instance of R.sup.P is hydrogen. In certain embodiments, at least one instance of R.sup.P is hydrogen. In certain embodiments, at least one instance of R.sup.P is halogen. In certain embodiments, at least one instance of R.sup.P is unsubstituted, C.sub.1-6 alkyl or C.sub.1-6 alkyl substituted with one or more halogen. In certain embodiments, at least one instance of R.sup.P is unsubstituted methyl.

[0195] In certain embodiments, at least one instance of R.sup.H is hydrogen. In certain embodiments, each instance of R.sup.H is hydrogen.

[0196] In certain embodiments, at least one instance of R.sup.H is substituted or unsubstituted alkyl (e.g., —CF.sub.3). In certain embodiments, at least one instance of R.sup.H is —CN. In certain embodiments, at least one instance of R.sup.H is —C(═O)OR.sup.a (e.g., —C(═O)OCH.sub.3). In certain embodiments, at least one instance of R.sup.H is —C(═O)R.sup.a. In certain embodiments, at least one instance of R.sup.H is —C(═O)N(R.sup.a).sub.2.

[0197] In certain embodiments, at least one instance of the first monomer is of the formula:

##STR00014##

[0198] In certain embodiments, at least one instance of the first monomer is of the formula:

##STR00015##

or salt thereof. In certain embodiments, at least one instance of the first monomer is of Formula (D1):

##STR00016##

or a salt thereof. In certain embodiments, each instance of the first monomer is of Formula (D1), or a salt thereof. In certain embodiments, at least one instance of the first monomer is of the formula:

##STR00017##

In certain embodiments, each instance of the first monomer is of the formula:

##STR00018##

In certain embodiments, each instance of the first monomer is of the formula:

##STR00019##

[0199] In certain embodiments, the two instances of R.sup.H of one or more instances of

##STR00020##

are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic carbocyclic ring, or substituted or unsubstituted, monocyclic heterocyclic ring. In certain embodiments, the two instances of R.sup.H of one or more instances of

##STR00021##

are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic cycloalkenyl ring. In certain embodiments, the two instances of R.sup.H of one or more instances of

##STR00022##

are joined with the intervening carbon atoms to independently form a substituted or unsubstituted, monocyclic, saturated heterocyclic ring. In certain embodiments, at least one instance of the first monomer comprises a substituted or unsubstituted partially unsaturated monocyclic carbocyclic ring or a substituted or unsubstituted partially unsaturated monocyclic heterocyclic ring.

[0200] In certain embodiments, at least one instance of the first monomer is of Formula (D2):

##STR00023##

or a salt thereof, wherein:

[0201] each instance of x is independently 0, 1, or 2; and

[0202] each instance of y is independently 0, 1, or 2.

[0203] In certain embodiments, each instance of the first monomer is of Formula (D2), or a salt thereof.

[0204] In certain embodiments, each instance of x is 0. In certain embodiments, each instance of x is 1. In certain embodiments, each instance of x is 2.

[0205] In certain embodiments, each instance of y is 1. In certain embodiments, each instance of y is 0. In certain embodiments, each instance of y is 2.

[0206] In certain embodiments, each instance of x is 1, and each instance of y is 1. In certain embodiments, each instance of x is 1, and each instance of y is 0. In certain embodiments, each instance of x is 0, and each instance of y is 1.

[0207] In certain embodiments, at least one instance of the first monomer is of the formula:

##STR00024##

preferably

##STR00025##

[0208] In certain embodiments, each instance of the first monomer is of the formula:

##STR00026##

In certain embodiments, each instance of the first monomer is of the formula:

##STR00027##

In certain embodiments, each instance of the first monomer is of the formula:

##STR00028##

[0209] In certain embodiments, at least one instance of the second monomer comprises one non-aromatic C═C or non-aromatic C═C bond. In certain embodiments, at least one instance of the second monomer comprises two, three, or four non-aromatic C═C and/or non-aromatic C═C bonds. In certain embodiments, at least one instance of the second monomer comprises two (i.e., only two) non-aromatic C═C and/or non-aromatic C═C bonds. In certain embodiments, at least one instance of the second monomer comprises only three non-aromatic C═C and/or non-aromatic C═C bonds (i.e., the combined number of non-aromatic C═C bonds and non-aromatic C═C bonds is three). In certain embodiments, at least one instance of the second monomer comprises no C═C bonds.

[0210] In certain embodiments, at least one instance of W is carbon. In certain embodiments, at least one instance of W is silicon.

[0211] In certain embodiments, at least one instance of Y is O. In certain embodiments, at least one instance of Y is CH.sub.2.

[0212] In certain embodiments, at least one instance of R.sup.Q is hydrogen.

[0213] In certain embodiments, at least one instance of R.sup.Y is hydrogen. In certain embodiments, each instance of R.sup.Y is independently hydrogen or unsubstituted C.sub.1-6 alkyl. In certain embodiments, at least one instance of R.sup.Y is substituted or unsubstituted, C.sub.1-6 alkyl.

[0214] In certain embodiments, at least one instance of R.sup.Z is hydrogen. In certain embodiments, each instance of R.sup.Z is independently hydrogen or unsubstituted C.sub.1-6 alkyl. In certain embodiments, at least one instance of R.sup.Z is substituted or unsubstituted, C.sub.1-6 alkyl.

[0215] In certain embodiments, j and k of at least one instance of the second monomer are 1 and 1, respectively. In certain embodiments, j and k of at least one instance of the second monomer are 1 and 2, or 2 and 1, respectively. In certain embodiments, j and k of at least one instance of the second monomer are 1 and 3, or 3 and 1, respectively. In certain embodiments, j and k of at least one instance of the second monomer are 2 and 2, respectively.

[0216] In certain embodiments, at least one instance of R.sup.K1 is substituted or unsubstituted, C.sub.1-10 alkyl, substituted or unsubstituted, C.sub.2-10 alkenyl, substituted or unsubstituted, C.sub.2-10 alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -L.sup.K1-(substituted or unsubstituted carbocyclyl), -L.sup.K1-(substituted or unsubstituted heterocyclyl), -L.sup.K1-(substituted or unsubstituted aryl), -L.sup.K1-(substituted or unsubstituted heteroaryl), or —OR.sup.N1.

[0217] In certain embodiments, at least one instance of R.sup.K is substituted or unsubstituted, C.sub.1-6 alkyl or substituted or unsubstituted phenyl.

[0218] In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is substituted or unsubstituted, C.sub.1-10 alkyl. In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is unsubstituted methyl, unsubstituted ethyl, unsubstituted propyl (e.g., unsubstituted n-propyl or unsubstituted isopropyl), or unsubstituted butyl (e.g., unsubstituted n-butyl).

[0219] In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is substituted or unsubstituted, saturated carbocyclyl. In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or unsubstituted cycloheptyl.

[0220] In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is substituted or unsubstituted, partially unsaturated carbocyclyl. In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is substituted or unsubstituted carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system. In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is unsubstituted cyclobutenyl, unsubstituted cyclopentenyl, unsubstituted cyclohexenyl, or unsubstituted cycloheptenyl. In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is substituted or unsubstituted carbocyclyl that comprises only two unsaturated bonds in the carbocyclic ring system. In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is substituted or unsubstituted carbocyclyl that comprises no C═C bonds in the carbocyclic ring system.

[0221] In certain embodiments, at least one instance of R.sup.K1 is:

##STR00029##

wherein:

##STR00030##

is Ring B′, wherein Ring B′ is a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring;

[0222] Z′ is C(R.sup.P′).sub.2 or O; [0223] each instance of R.sup.P′ is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl;

[0224] custom-character is a single bond or double bond;

[0225] each instance of R.sup.H′ is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR.sup.a, —OCN, —OC(═O)R.sup.a, —OC(═S)R.sup.a, —OC(═O)OR.sup.a, —OC(═O)N(R.sup.a).sub.2, —OS(═O)R.sup.a, —OS(═O)OR.sup.a, —OS(═O)N(R.sup.a).sub.2, —OS(═O).sub.2R.sup.a, —OS(═O).sub.2OR.sup.a, —OS(═O).sub.2N(R.sup.a).sub.2, —OSi(R.sup.a).sub.3, —OSi(R.sup.a).sub.2(OR.sup.a), —OSi(R.sup.a)(OR.sup.a).sub.2, —OSi(OR.sup.a).sub.3, oxo, —N(R.sup.a).sub.2, —N═C(R.sup.a).sub.2, ═NR.sup.a, —NC, —NCO, —N.sub.3, —NO.sub.2, —NR.sup.aC(═O)R.sup.a, —NR.sup.aC(═O)OR.sup.a, —NR.sup.aC(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O)R.sup.a, —NR.sup.aS(═O)OR.sup.a, —NR.sup.aS(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O).sub.2R.sup.a, —NR.sup.aS(═O).sub.2OR.sup.a, —NR.sup.aS(═O).sub.2N(R.sup.a).sub.2, —SR.sup.a, —SCN, —S(═O)R.sup.a, —S(═O)OR.sup.a, —S(═O)N(R.sup.a).sub.2, —S(═O).sub.2R.sup.a, —S(═O).sub.2OR.sub.a, —S(═O).sub.2N(R.sup.a).sub.2, —SeR.sup.a, halogen, —CN, —C(═NR.sup.a)R.sup.a, —C(═NR.sup.a)OR.sup.a, —C(═NR.sup.a)N(R.sup.a).sub.2, —C(═O)R.sup.a, —C(═O)OR.sup.a, —C(═O)SR.sup.a, —C(═S)OR.sup.a, or —C(═O)N(R.sup.a).sub.2;

[0226] or the two instances of R.sup.H′ are joined with the intervening carbon atoms to form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring; and

[0227] each instance of R.sup.a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R.sup.a are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl.

[0228] In certain embodiments, at least one instance of R.sup.K1 is:

##STR00031##

[0229] In certain embodiments, Ring B′ is substituted or unsubstituted, monocyclic carbocyclic ring. In certain embodiments, Ring B′ is substituted or unsubstituted, monocyclic, saturated carbocyclyl. In certain embodiments, Ring B′ is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or unsubstituted cycloheptyl. In certain embodiments, Ring B′ is substituted or unsubstituted, monocyclic, partially unsaturated carbocyclyl. In certain embodiments, Ring B′ is substituted or unsubstituted, monocyclic carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system. In certain embodiments, Ring B′ is unsubstituted cyclobutenyl, unsubstituted cyclopentenyl, unsubstituted cyclohexenyl, or unsubstituted cycloheptenyl. In certain embodiments, Ring B′ is substituted or unsubstituted, monocyclic carbocyclyl that comprises only two unsaturated bonds in the carbocyclic ring system. In certain embodiments, Ring B′ is substituted or unsubstituted, monocyclic carbocyclyl that comprises no C=C bonds in the carbocyclic ring system.

[0230] In certain embodiments, Z′ is CH.sub.2.

[0231] In certain embodiments, each R.sup.H′ is hydrogen. In certain embodiments, two instances of R.sup.H′ are joined with the intervening carbon atoms to form an unsubstituted monocyclic carbocyclic ring. In certain embodiments, two instances of R.sup.H′ are joined with the intervening carbon atoms to form an unsubstituted monocylic heterocyclic ring.

[0232] In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is

##STR00032##

[0233] In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is -(substituted or unsubstituted, C.sub.1-10 alkylene)-(substituted or unsubstituted, partially unsaturated carbocyclyl). In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is -(unsubstituted C.sub.1-10 alkylene)-(substituted or unsubstituted carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system).

[0234] In certain embodiments, at least one instance of R.sup.K1 is substituted or unsubstituted heterocyclyl or -L.sup.K1-(substituted or unsubstituted heterocyclyl). In certain embodiments, at least one instance of R.sup.K1 is substituted or unsubstituted heterocyclyl that comprises O—Si in the heterocyclic ring system or -L.sup.K1-(substituted or unsubstituted heterocyclyl that comprises O—Si in the heterocyclic ring system). In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is -(substituted or unsubstituted, C.sub.1-10 alkylene)-(substituted or unsubstituted heterocyclyl). In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is -(substituted or unsubstituted, C.sub.1-10 alkylene)-(substituted or unsubstituted heterocyclyl that comprises OSi in the heterocyclic ring system). In certain embodiments, at least one instance of R.sup.K1 is:

##STR00033##

In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is -(substituted or unsubstituted phenylene)-(substituted or unsubstituted, partially unsaturated heterocyclyl). In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is -(substituted or unsubstituted phenylene)-(substituted or unsubstituted heterocyclyl that comprises only one unsaturated bond in the heterocyclic ring system). In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is -(substituted or unsubstituted phenylene)-(substituted or unsubstituted, partially unsaturated heterocyclyl that comprises O—Si in the heterocyclic ring system). In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is -(substituted or unsubstituted phenylene)-(substituted or unsubstituted heterocyclyl that comprises O—Si and only one unsaturated bond in the heterocyclic ring system).

[0235] In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is

##STR00034##

In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is

##STR00035##

[0236] In certain embodiments, at least one instance of R.sup.K1 or at least one first instance of R.sup.K of a second monomer is hydrogen. In certain embodiments, at least one instance of R.sup.K1 is —OR.sup.N1 (e.g., —O(substituted or unsubstituted, C.sub.1-10 alkyl)).

[0237] In certain embodiments, at least one first instance of R.sup.K of a second monomer is —OR.sup.N1 (e.g., —O(substituted or unsubstituted, C.sub.1-10 alkyl)).

[0238] In certain embodiments, at least one instance of R.sup.N1 is substituted or unsubstituted, C.sub.1-10 alkyl. In certain embodiments, at least one instance of R.sup.N1 is unsubstituted C.sub.1-6 alkyl.

[0239] In certain embodiments, at least one instance of L.sup.K1 is —O— or substituted or unsubstituted, C.sub.1-10 alkylene. In certain embodiments, at least one instance of L.sup.K1 is unsubstituted C.sub.1-6 alkylene. In certain embodiments, at least one instance of L.sup.K1 is substituted or unsubstituted phenylene.

[0240] In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is substituted or unsubstituted, saturated carbocyclyl. In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or unsubstituted cycloheptyl.

[0241] In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is substituted or unsubstituted, partially unsaturated carbocyclyl. In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is substituted or unsubstituted carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system. In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is unsubstituted cyclobutenyl, unsubstituted cyclopentenyl, unsubstituted cyclohexenyl, or unsubstituted cycloheptenyl. In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is substituted or unsubstituted carbocyclyl that comprises only two unsaturated bonds in the carbocyclic ring system. In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is substituted or unsubstituted carbocyclyl that comprises no C═C bonds in the carbocyclic ring system.

[0242] In certain embodiments, at least one instance of R.sup.K2 is:

##STR00036##

wherein:

##STR00037##

is Ring B″, wherein Ring B″ is a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring;

[0243] Z″ is C(R.sup.P″).sub.2 or O;

[0244] each instance of R.sup.P″ is independently hydrogen, halogen, or substituted or unsubstituted, C.sub.1-6 alkyl;

[0245] custom-character is a single bond or double bond;

[0246] each instance of R.sup.H″ is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —OR.sup.a, —OCN, —OC(═O)R.sup.a, —OC(═S)R.sup.a, —OC(═O)OR.sup.a, —OC(═O)N(R.sup.a).sub.2, —OS(═O)R.sup.a, —OS(═O)OR.sup.a, —OS(═O)N(R.sup.a).sub.2, —OS(═O).sub.2R.sup.a, —OS(═O).sub.2l R.sup.a, —OS(═O).sub.2N(R.sup.a).sub.2, —OSi(R.sup.a).sub.3, —OSi(R.sup.a).sub.2(OR.sup.a), —OSi(R.sup.a)(OR.sup.a).sub.2, —OSi(OR.sup.a).sub.3, oxo, —N(R.sup.a).sub.2, —N═C(R.sup.a).sub.2, ═NR.sup.a, —NC, —NCO, —N.sub.3, —NO.sub.2, —NR.sup.aC(═O)R.sup.a, —NR.sup.aC(═O)OR.sup.a, —NR.sup.aC(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O)R.sup.a, —NR.sup.aS(═O)OR.sup.a, —NR.sup.aS(═O)N(R.sup.a).sub.2, —NR.sup.aS(═O).sub.2R.sup.a, —NR.sup.aS(═O).sub.2OR.sup.a, —NR.sup.aS(═O).sub.2N(R.sup.a).sub.2, —SR.sup.a, —SCN, —S(═O)R.sup.a, —S(═O)OR.sup.a, —S(═O)N(R.sup.a).sub.2, —S(═O).sub.2R.sup.a, —S(═O).sub.2OR.sup.a, —S(═O).sub.2N(R.sup.a).sub.2, —SeR.sup.a, halogen, —CN, —C(═NR.sup.a)R.sup.a, —C(═NR.sup.a)OR.sup.a, —C(═NR.sup.a)N(R.sup.a).sub.2, —C(═O)R.sup.a, —C(═O)OR.sup.a, —C(═O)SR.sup.a, —C(═S)OR.sup.a, or —C(═O)N(R.sup.a).sub.2;

[0247] or the two instances of R.sup.H″ are joined with the intervening carbon atoms to form a substituted or unsubstituted, monocyclic carbocyclic ring, substituted or unsubstituted, monocyclic heterocyclic ring, substituted or unsubstituted, monocyclic aryl ring, or substituted or unsubstituted, monocyclic heteroaryl ring; and

[0248] each instance of R.sup.a is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted, monocyclic carbocyclyl, substituted or unsubstituted, monocyclic heterocyclyl, substituted or unsubstituted, monocyclic aryl, substituted or unsubstituted, monocyclic heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R.sup.a are joined to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl.

[0249] In certain embodiments, at least one instance of R.sup.K2 is:

##STR00038##

[0250] In certain embodiments, Ring B″ is substituted or unsubstituted, monocyclic carbocyclic ring. In certain embodiments, Ring B″ is substituted or unsubstituted, monocyclic, saturated carbocyclyl. In certain embodiments, Ring B″ is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl, or unsubstituted cycloheptyl. In certain embodiments, Ring B″ is substituted or unsubstituted, monocyclic, partially unsaturated carbocyclyl. In certain embodiments, Ring B″ is substituted or unsubstituted, monocyclic carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system. In certain embodiments, Ring B″ is unsubstituted cyclobutenyl, unsubstituted cyclopentenyl, unsubstituted cyclohexenyl, or unsubstituted cycloheptenyl. In certain embodiments, Ring B″ is substituted or unsubstituted, monocyclic carbocyclyl that comprises only two unsaturated bonds in the carbocyclic ring system. In certain embodiments, Ring B″ is substituted or unsubstituted, monocyclic carbocyclyl that comprises no C═C bonds in the carbocyclic ring system.

[0251] In certain embodiments, Z″ is CH.sub.2.

[0252] In certain embodiments, each R.sup.H″ is hydrogen. In certain embodiments, two instances of R.sup.H″ are joined with the intervening carbon atoms to form an unsubstituted monocyclic carbocyclic ring. In certain embodiments, two instances of R.sup.H″ are joined with the intervening carbon atoms to form an unsubstituted monocylic heterocyclic ring.

[0253] In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is

##STR00039##

[0254] In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is -(substituted or unsubstituted, C.sub.1-10 alkylene)-(substituted or unsubstituted, partially unsaturated carbocyclyl). In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is -(unsubstituted C.sub.1-10 alkylene)-(substituted or unsubstituted carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system).

[0255] In certain embodiments, at least one instance of R.sup.K2 is substituted or unsubstituted heterocyclyl or -L.sup.K2-(substituted or unsubstituted heterocyclyl). In certain embodiments, at least one instance of R.sup.K2 is substituted or unsubstituted heterocyclyl that comprises O—Si in the heterocyclic ring system or -L.sup.K2-(substituted or unsubstituted heterocyclyl that comprises O—Si in the heterocyclic ring system). In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is -(substituted or unsubstituted, C.sub.1-10 alkylene)-(substituted or unsubstituted heterocyclyl). In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is -(substituted or unsubstituted, C.sub.1-10 alkylene)-(substituted or unsubstituted heterocyclyl that comprises O—Si in the heterocyclic ring system). In certain embodiments, at least one instance of R.sup.K2 is:

##STR00040##

In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is -(substituted or unsubstituted phenylene)-(substituted or unsubstituted, partially unsaturated heterocyclyl). In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is -(substituted or unsubstituted phenylene)-(substituted or unsubstituted heterocyclyl that comprises only one unsaturated bond in the heterocyclic ring system). In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is -(substituted or unsubstituted phenylene)-(substituted or unsubstituted, partially unsaturated heterocyclyl that comprises O—Si in the heterocyclic ring system). In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is -(substituted or unsubstituted phenylene)-(substituted or unsubstituted heterocyclyl that comprises O—Si and only one unsaturated bond in the heterocyclic ring system).

[0256] In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is

##STR00041##

In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is

##STR00042##

[0257] In certain embodiments, at least one instance of R.sup.K2 or at least one second instance of R.sup.K of the second monomer is hydrogen. In certain embodiments, at least one instance of R.sup.K2 is —OR.sup.N2 (e.g., —O(substituted or unsubstituted, C.sub.1-10 alkyl)).

[0258] In certain embodiments, at least one instance of R.sup.N2 is substituted or unsubstituted, C.sub.1-10 alkyl. In certain embodiments, at least one instance of R.sup.N2 is unsubstituted C.sub.1-6 alkyl.

[0259] In certain embodiments, at least one instance of L.sup.K2 is —O— or substituted or unsubstituted, C.sub.1-10 alkylene. In certain embodiments, at least one instance of L.sup.K2 is unsubstituted C.sub.1-6 alkylene. In certain embodiments, at least one instance of L.sup.K2 is substituted or unsubstituted phenylene.

[0260] In certain embodiments, at least one second instance of R.sup.K of the second monomer is substituted or unsubstituted, C.sub.1-10 alkyl. In certain embodiments, at least one second instance of R.sup.K of the second monomer is unsubstituted methyl, unsubstituted ethyl, unsubstituted propyl (e.g., unsubstituted n-propyl or unsubstituted isopropyl), or unsubstituted butyl (e.g., unsubstituted n-butyl). In certain embodiments, at least one second instance of R.sup.K of the second monomer is substituted or unsubstituted phenyl. In certain embodiments, at least one second instance of R.sup.K of the second monomer is —OR.sup.N (e.g., —O(substituted or unsubstituted, C.sub.1-10 alkyl)).

[0261] In certain embodiments, R.sup.K1 and R.sup.K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, partially unsaturated carbocyclyl. In certain embodiments, R.sup.K1 and R.sup.K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, monocyclic carbocyclyl that comprises only one unsaturated bond in the carbocyclic ring system. In certain embodiments, R.sup.K1 and R.sup.K2 of at least one instance of the second monomer are joined with the intervening atom to form unsubstituted cyclobutenyl, unsubstituted cyclopentenyl, unsubstituted cyclohexenyl, or unsubstituted cycloheptenyl. In certain embodiments, R.sup.K1 and R.sup.K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, monocyclic carbocyclyl that comprises only two unsaturated bonds in the carbocyclic ring system. In certain embodiments, R.sup.K1 and R.sup.K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted carbocyclyl that comprises no C═C bonds in the carbocyclic ring system.

[0262] In certain embodiments, R.sup.K1 and R.sup.K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, partially unsaturated heterocyclyl. In certain embodiments, R.sup.K1 and R.sup.K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, monocyclic heterocyclyl that comprises only one unsaturated bond in the heterocyclic ring system. In certain embodiments, R.sup.K1 and R.sup.K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted, monocyclic heterocyclyl that comprises only two unsaturated bonds in the heterocyclic ring system. In certain embodiments, R.sup.K1 and R.sup.K2 of at least one instance of the second monomer are joined with the intervening atom to form substituted or unsubstituted heterocyclyl that comprises no C═C bonds in the heterocyclic ring system.

[0263] In certain embodiments, at least one instance of the second monomer comprises only one non-aromatic unsaturated bond. In certain embodiments, each instance of the second monomer comprises only one non-aromatic unsaturated bond. In certain embodiments, at least one instance of the second monomer comprises only two non-aromatic unsaturated bonds.

[0264] In certain embodiments, the C═C bond in the heterocyclic ring that comprises O—W—Y is of the (Z)-configuration. In certain embodiments, the C═C bond in the heterocyclic ring that comprises O—W—Y is of the (E)-configuration.

[0265] In certain embodiments, at least one instance of the second monomer is of the formula:

##STR00043##

or a salt thereof.

[0266] In certain embodiments, at least one instance of the second monomer is of the formula:

##STR00044##

or a salt thereof.

[0267] In certain embodiments, at least one instance of the second monomer is of the formula:

##STR00045##

[0268] In certain embodiments, at least one instance of the second monomer is of the formula:

##STR00046##

or a salt thereof.

[0269] In certain embodiments, at least one instance of the second monomer is of the formula:

##STR00047##

or a salt thereof.

[0270] In certain embodiments, at least one instance of the second monomer is of the formula:

##STR00048##

or a salt thereof.

[0271] In certain embodiments, at least one instance of the second monomer is of the formula:

##STR00049##

[0272] In certain embodiments, at least one instance of the second monomer is of the formula:

##STR00050##

[0273] In certain embodiments, at least one instance of the second monomer is of the formula:

##STR00051##

[0274] In certain embodiments, at least one instance of the second monomer is of the formula:

##STR00052##

[0275] In certain embodiments, the molar ratio of the first monomer to the second monomer is between 1:1 and 100:1, inclusive. In certain embodiments, the molar ratio of the first monomer to the second monomer is between 3:1 and 30:1, inclusive. In certain embodiments, the molar ratio of the first monomer to the second monomer is between 1:1 and 3:1, between 3:1 and 10:1, between 10:1 and 30:1, or between 30:1 and 100:1, inclusive.

[0276] In certain embodiments, the method of preparing the copolymer further comprises exposing the copolymer to a solvent.

[0277] In certain embodiments, the method of preparing the copolymer further comprises solid-liquid phase separation.

[0278] In certain embodiments, the method of preparing the copolymer further comprises curing.

[0279] In some embodiments, curing forms a resin. In certain embodiments, curing is carried out at 70 to 150° C., inclusive. In certain embodiments, curing is carried out at 100 to 150° C., inclusive. In certain embodiments, curing is carried out at 100 to 130° C., inclusive. In certain embodiments, curing is carried out at 110 to 120° C., inclusive. In some embodiments, curing is carried out at about 110° C. In some embodiments, curing is carried out at about 120° C. In some embodiments, curing is carried out for 1 minute to 3 hours, inclusive. In some embodiments, curing is carried out for 15 minutes to 1 hour, inclusive. In some embodiments, curing is carried out for 15 minutes. In certain embodiments, curing is carried out for 30 minutes. In some embodiments, curing is carried out for 1 hour. In certain embodiments, curing is carried out at ambient pressure. In some embodiments, curing is carried out at lower-than-ambient pressure. In some embodiments, curing is carried out at higher-than-ambient pressure.

[0280] The preparation of the copolymers may involve a metathesis reaction. In certain embodiments, the metathesis reaction is a ring-opening metathesis polymerization (ROMP) (see, e.g., Liu et al. J. Am. Chem. Soc. 2012, 134, 16337; Liu, J.; Gao, A. X.; Johnson, J. A. J V is Exp 2013, e50874).

[0281] In certain embodiments, the metathesis catalyst (e.g., ROMP catalyst) is a tungsten (W), molybdenum (Mo), or ruthenium (Ru) catalyst. In certain embodiments, the metathesis catalyst is a ruthenium catalyst. Metathesis catalysts useful in the synthetic methods described herein include catalysts as depicted below, and as described in Grubbs et al., Acc. Chem. Res. 1995, 28, 446-452; U.S. Pat. No. 5,811,515; Schrock et al., Organometallics (1982) 1 1645; Gallivan et al., Tetrahedron Letters (2005) 46:2577-2580; Furstner et al., J. Am. Chem. Soc. (1999) 121:9453; and Chem. Eur. J. (2001) 7:5299; the entire contents of each of which are incorporated herein by reference.

[0282] In certain embodiments, the metathesis catalyst is a ruthenium metathesis catalyst. In certain embodiments, the metathesis catalyst is a Grubbs' catalyst. In certain embodiments, the Grubbs' catalyst is selected from the group consisting of:

##STR00053## [0283] Benzylidenebis (tricyclohexylphosphine)dichlororuthenium (X═Cl); Benzylidenebis-(tricyclohexylphosphine)-dibromoruthenium (X═Br); Benzylidenebis-(tricyclohexylphosphine)diiodoruthenium (X═I);

##STR00054## [0284] 1,3-(Bis(mesityl)-2-imidazolidinylidene)dichloro-(phenylmethylene) (tricyclohexyl-phosphine)ruthenium (X=Cl; R=cyclohexyl); 1,3-(Bis(mesityl)-2-imidazolidinylidene)dibromo-(phenylmethylene) (tricyclohexyl-phosphine)ruthenium (X=Br; R=cyclohexyl); 1,3-(Bis(mesityl)-2-imidazolidinylidene)diiodo-(phenylmethylene) (tricyclohexyl-phosphine)ruthenium (X=I; R=cyclohexyl); 1,3-(Bis(mesityl)-2-imidazolidinylidene)dichloro-(phenylmethylene) (triphenylphosphine)ruthenium (X=Cl; R=phenyl); 1,3-(Bis(mesityl)-2-imidazolidinylidene)dichloro-(phenylmethylene) (tribenzylphosphine)ruthenium (X=Cl; R=benzyl);

##STR00055##

[0285] In certain embodiments, the metathesis catalyst is a Grubbs-Hoveyda catalyst. In certain embodiments, the Grubbs-Hoveyda catalyst is selected from the group consisting of:

##STR00056##

[0286] In certain embodiments, the metathesis catalyst is selected from the group consisting of:

##STR00057##

[0287] In certain embodiments, the metathesis catalyst is of the formula:

##STR00058##

[0288] The ROMP can be conducted in one or more aprotic solvents. The term “aprotic solvent” means a non-nucleophilic solvent having a boiling point range above ambient temperature, preferably from about 25° C. to about 190° C. at atmospheric pressure. In certain embodiments, the aprotic solvent has a boiling point from about 80° C. to about 160° C. at atmospheric pressure. In certain embodiments, the aprotic solvent has a boiling point from about 80° C. to about 150° C. at atmospheric pressure. Examples of such solvents are methylene chloride, acetonitrile, toluene, DMF, diglyme, THF, and DMSO.

[0289] The ROMP can be quenched with a vinyl ether of the formula

##STR00059##

Each of R.sup.V1, R.sup.V2, R.sup.V3, and R.sup.V4 is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted phenyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl. In certain embodiments, R.sup.V1 is optionally substituted alkyl, and R.sup.V2, R.sup.V3, and R.sup.V4 are hydrogen. In certain embodiments, R.sup.V1 is unsubstituted alkyl, and R.sup.V2, R.sup.V3, and R.sup.V4 are hydrogen. In certain embodiments, R.sup.V1 is substituted alkyl, and R.sup.V2, R.sup.V3, and R.sup.V4 are hydrogen. In certain embodiments, R.sup.V1 is methyl, and R.sup.V2, R.sup.V3, and R.sup.V4 are hydrogen. In certain embodiments, R.sup.V1 is ethyl, and R.sup.V2, R.sup.V3, and R.sup.V4 are hydrogen. In certain embodiments, R.sup.V1 is propyl, and R.sup.V2, R.sup.V3, and R.sup.V4 are hydrogen. In certain embodiments, R.sup.V1 is optionally substituted alkenyl, and R.sup.V2, R.sup.V3, and R.sup.V4 are hydrogen. In certain embodiments, R.sup.V1 is unsubstituted alkenyl, and R.sup.V2, R.sup.V3, and R.sup.V4 are hydrogen. In certain embodiments, R.sup.V1 is vinyl, and R.sup.V2, R.sup.V3, and R.sup.V4 are hydrogen. In certain embodiments, at least one of R.sup.V1, R.sup.V2, R.sup.V3, and R.sup.V4 is conjugated with a diagnostic agent as defined above. In certain embodiments, the ROMP is quenched by ethyl vinyl ether. Excess ethyl vinyl ether can be removed from the copolymer by vacuum.

[0290] In certain embodiments, the ratio of the combined molar amounts of the first monomer, second monomer, and third monomer if present to the molar amount of the metathesis catalyst is between 500:1 and 1,000:1, between 1,000:1 and 3,000:1, between 3,000:1 and 10,000:1, between 10,000:1 and 30,000:1, between 30,000:1 and 100,000:1, or between 100,000:1 and 500,000:1, inclusive. In certain embodiments, the ratio of the combined molar amounts of the first monomer, second monomer, and third monomer if present to the molar amount of the metathesis catalyst is between 500:1 and 500,000:1, inclusive. In certain embodiments, the ratio of the combined molar amounts of the first monomer, second monomer, and third monomer if present to the molar amount of the metathesis catalyst is between 1,000:1 and 6,000:1, inclusive. In certain embodiments, the ratio of the combined molar amounts of the first monomer, second monomer, and third monomer if present to the molar amount of the metathesis catalyst is between 2,000:1 and 3,000:1, inclusive.

[0291] In certain embodiments, the crosslinking degree of the copolymer is between 1% and 10%, between 10% and 20%, between 20% and 30%, between 30% and 40%, or between 40% and 50%, inclusive, mole:mole. In certain embodiments, the crosslinking degree of the copolymer is between 1% and 50%, inclusive, mole:mole. In certain embodiments, the crosslinking degree of the copolymer is between 10% and 30%, inclusive, mole:mole. In certain embodiments, the crosslinking degree of the copolymer is between 15% and 20%, inclusive, mole:mole.

[0292] In certain embodiments, the average molecular weight of the copolymer as determined by gel permeation chromatography is between 10 kDa and 100,000 kDa, inclusive. In certain embodiments, the average molecular weight of the copolymer as determined by gel permeation chromatography is between 10 kDa and 100 kDa, between 100 kDa and 1,000 kDa, between 1,000 kDa and 10,000 kDa, between 10,000 kDa and 100,000 kDa, inclusive. In certain embodiments, the average molecular weight of the copolymer as determined by gel permeation chromatography is a number average molecular weight.

[0293] In certain embodiments, the copolymer is a random copolymer.

[0294] In certain embodiments, the reprocessing catalyst is a Brønsted acid, or a salt thereof. In certain embodiments, the reprocessing catalyst is a Brønsted acid, or a salt thereof, wherein the pKa of the Brønsted acid is between 0 and 6 (e.g., between 0 and 2, between 2 and 4, between 4 and 6), inclusive, as determined at about 20° C. in an aqueous solution. In certain embodiments, the reprocessing catalyst is selected from the group consisting of sulfonic acids, sulfinic acids, sulfonamides, sulfinimides, phosphoric acids, phosphonic acids, tetrazoles, and salts thereof. In certain embodiments, the reprocessing catalyst is a sulfonic acid. In certain embodiments, the reprocessing catalyst is camphor sulfonic acid. In certain embodiments, the reprocessing catalyst is a carboxylic acid. In certain embodiments, the reprocessing catalyst is a salt of a carboxylic acid. In certain embodiments, the reprocessing catalyst is an alkali metal salt, alkaline earth metal salt, or NH.sub.4.sup.+ salt, of a carboxylic acid. In certain embodiments, the reprocessing catalyst is an unsubstituted C.sub.2-20 alkanoic acid. In certain embodiments, the reprocessing catalyst is unsubstituted n-octanoic acid. In certain embodiments, the reprocessing catalyst is a salt (e.g., alkali metal salt) of unsubstituted n-octanoic acid. In certain embodiments, the reprocessing catalyst is a Lewis acid. In certain embodiments, the reprocessing catalyst is a Lewis acid, and the Lewis acid comprises B(III), Al(III), Sc(III), Ti(IV), Fe(II), Fe(III), Zn(II), or Sn(II). In certain embodiments, the reprocessing catalyst is a Lewis acid, and the Lewis acid does not comprise Zn(II). In certain embodiments, the reprocessing catalyst is a Lewis acid, and the Lewis acid comprises B(III), Al(III), Sc(III), Ti(IV), Fe(II), Fe(III), or Sn(II).

[0295] In certain embodiments, the reprocessing catalyst is a Lewis base, or a salt thereof. In certain embodiments, the reprocessing catalyst is a salt of a Lewis base, and the salt of the Lewis base comprises anilinium, pyridinium, triazolium, or imidazolium. In certain embodiments, the reprocessing catalyst is an unsubstituted non-aromatic cyclic amine (e.g., where at least one nitrogen atom is a non-aromatic ring atom). In certain embodiments, the reprocessing catalyst is 1,8-diazabicyclo[5.4.0]undec-7-ene. In certain embodiments, the reprocessing catalyst is an unsubstituted trialkyl amine. In certain embodiments, the reprocessing catalyst is an aromatic amine. In certain embodiments, the reprocessing catalyst is N,N-diisopropylethylamine, 1,5-diazabicyclo(4.3.0)non-5-ene, 2,6-di-tert-butylpyridine, a phosphazene base, lithium diisopropylamide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, or lithium tetramethylpiperidide.

[0296] In certain embodiments, the reprocessing catalyst is selected from the group consisting of ureas, thioureas, carbamates, thiocarbamates, xanthates, thiocarboxylic acids, dithiocarboxylic acids, and salts thereof. In certain embodiments, the reprocessing catalyst is a urea, thiourea, carbamate, thiocarbamate, or a salt thereof.

[0297] In certain embodiments, the reprocessing catalyst is not an ammonium halide. In certain embodiments, the reprocessing catalyst is not zinc triflate, lithium methoxide, tetra-n-butylammonium fluoride, ammonium chloride, or zinc acetylacetonate. In certain embodiments, the reprocessing catalyst is not camphor sulfonic acid. In certain embodiments, the reprocessing catalyst is not DBU.

[0298] In certain embodiments, the molar ratio of the second monomer to the reprocessing catalyst is between 30:1 and 1:10, inclusive. In certain embodiments, the molar ratio of the second monomer to the reprocessing catalyst is between 30:1 and 10:1, between 10:1 and 3:1, between 3:1 and 1:1, between 1:1 and 0.3:1, or between 0.3:1 and 0.1:1, inclusive.

[0299] In certain embodiments, the molar ratio of the second monomer to the reprocessing catalyst is between 5:1 and 1:2, inclusive. In certain embodiments, the molar ratio of the second monomer to the reprocessing catalyst is between 10:3 and 5:6, inclusive. In certain embodiments, the molar ratio of the second monomer to the reprocessing catalyst is between 100:1 and 30:1, between 30:1 and 10:1, between 10:1 and 3:1, between 3:1 and 1:1, or between 1:1 and 0.3:1, inclusive.

EXAMPLES

[0300] In order that the invention described herein may be more fully understood, the following examples are set forth. The synthetic and biological examples described herein are offered to illustrate the present disclosure and are not to be construed in any way as limiting their scope.

Example 1: Preparation of DCPD-co-iPrSi

[0301] Dicyclopentadiene (DCPD) was distilled to remove impurities. DCPD was heated to 40° C. and mixed with iPrSi (either 10% or 20%, v/v), then added to finely powdered Grubbs' 2nd generation catalyst (GII) at a final concentration of 2 mg GII/mL monomer. The resulting mixture was vortexed until all solids were dissolved, then added in 150 μL aliquots to vials and cured at 120° C. for 30 minutes.

Example 2: Remolding of DCPD-co-iPrSi

[0302] DCPD-co-iPrSi, prepared as described in Example 1, was swollen in THF overnight, finely cut, then dried overnight under vacuum. The dried DCPD-co-iPrSi was then run under a hand grinder to reduce the size further. The ground DCPD-co-iPrSi was then soaked with a reprocessing catalyst (e.g., OA) in THF overnight, after which THF was removed under vacuum, the residue was dried under vacuum at 60° C. overnight. The dried residue was loaded into a sheet mold and hot pressed at the described time, temperature, and pressure. The results showed that the combinations of iPrSi in DCPD-co-iPrSi and the reprocessing catalyst (e.g., OA) allowed DCPD-co-iPrSi to be remolded. These constitute covalent adaptable networks with 100% static crosslinks and no dangling functionalities required for exchange.

Example 3: Set-Up of Small-Molecule Model Exchange Experiments

[0303] ##STR00060##

and octanoic acid (10 mol %) were added to a 4 mL vial, sealed, and heated in a reaction Pie-Block for 18 h. The reaction mixture was cooled, and an aliquot taken and diluted to 50 ppm in DCM for analysis via GC-MS. Exemplary results are shown in FIG. 4C.

EQUIVALENTS AND SCOPE

[0304] In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

[0305] Furthermore, the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

[0306] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any claim, for any reason, whether or not related to the existence of prior art.

[0307] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.

REPROCESSABLE COMPOSITIONS

Inventors

Cpc classification

Classification Explorer

C08L65/00

CHEMISTRY; METALLURGY

Classification Explorer

C08G61/08

CHEMISTRY; METALLURGY

Classification Explorer

C08G61/02

CHEMISTRY; METALLURGY

Classification Explorer

C08G2261/1414

CHEMISTRY; METALLURGY

Classification Explorer

C08G61/12

CHEMISTRY; METALLURGY

Classification Explorer

C08G2261/418

CHEMISTRY; METALLURGY

Classification Explorer

C08G2261/314

CHEMISTRY; METALLURGY

Classification Explorer

C08G2261/3222

CHEMISTRY; METALLURGY

Classification Explorer

C08G2261/1412

CHEMISTRY; METALLURGY

Classification Explorer

C08G2261/3324

CHEMISTRY; METALLURGY

Classification Explorer

C08G2261/3321

CHEMISTRY; METALLURGY

Classification Explorer

C08G2261/12

CHEMISTRY; METALLURGY

Classification Explorer

C08G2261/144

CHEMISTRY; METALLURGY

Classification Explorer

C08G2261/70

CHEMISTRY; METALLURGY

International classification

Classification Explorer

C08G61/02

CHEMISTRY; METALLURGY

Classification Explorer

C08G61/12

CHEMISTRY; METALLURGY

Abstract

Claims

Description